Estudos Randomizados

Estudo randomizado | Ustequinumabe não melhora os desfechos de pacientes com lúpus eritematoso sistêmico.

11 Jul, 2022 | 13:44h

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus – Annals of Rheumatic Diseases

 

---

Estudo randomizado | Balovaptam não é melhor que placebo para a comunicação social no transtorno do espectro autista infantil.

11 Jul, 2022 | 13:43h

Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial – JAMA Psychiatry

 

Comentário no Twitter

In this RCT, balovaptan did not demonstrate efficacy in improvement of socialization and communication in pediatric autism spectrum disorder (ASD), highlighting challenges faced in #ASD trial design, such as outcome measure sensitivity & placebo response. https://t.co/FFAJeu5xv0

— JAMA Psychiatry (@JAMAPsych) July 6, 2022

 

---

Estudo randomizado | Efeitos relacionados a dose de quetamina para sintomas resistentes a antidepressivos do transtorno do estresse pós-traumático em militares veteranos e ativos.

11 Jul, 2022 | 13:36h

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial – Neuropsychopharmacology (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

Glad to see this work published. Contrary to predictions from small studies, #ketamine failed in the largest #PTSD clinical trial.

Future studies should test the lower dose and 3x/wk. @npp_journal @YalePsych @bcmhouston @netteaverillhttps://t.co/7NcFsNTMKw

— Chadi Abdallah (@ChadiAbdallah3) January 19, 2022

 

---

Estudo randomizado | Eficácia e segurança do upadacitinibe para espondilite anquilosante ativa refratária à terapia biológica.

8 Jul, 2022 | 11:15h

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial – Annals of Rheumatic Diseases

 

Comentário no Twitter

SELECT-AXIS 2 trial – patients with #AS and inadequate response to #bDMARDs. #RCT of upadacitinb vs placebo 14 weeks:
Improved signs and symptoms of active AS and was well tolerated for 14 weeks of treatment in bDMARD-IR patients!https://t.co/Z7fuxiXMDb pic.twitter.com/kGZX9AsaVE

— ARD & RMD Open (@ARD_BMJ) July 5, 2022

 

---

Estudo randomizado | Tratamento com odevixibate na colestase intra-hepática familiar progressiva.

7 Jul, 2022 | 12:11h

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial – The Lancet Gastroenterology & Hepatology

Invited Commentary: The first new drug for progressive familial intrahepatic cholestasis – The Lancet Gastroenterology & Hepatology (necessário cadastro gratuito)

 

Comentário no Twitter

New research – Thompson et al – Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial (PEDFIC 1)https://t.co/hPLmPLMcDt#livertwitter #cholestasis #PFIC pic.twitter.com/oUMMh1H0kv

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 1, 2022

 

---

Estudo randomizado | Enterosgel (polidrato de polimetilsiloxano) para tratamento da síndrome do intestino irritável com diarreia.

7 Jul, 2022 | 12:08h

Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D) – Gut

---

Estudo randomizado | Teste dos efeitos da combinação de azitromicina com tobramicina inalatória para P. aeruginosa na fibrose cística.

7 Jul, 2022 | 12:07h

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial – Thorax

Comentário: Does Azithromycin antagonize the effect of inhaled tobramycin in cystic fibrosis? – Medical Dialogues

 

Comentário no Twitter

Original research: Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trialhttps://t.co/z9dGX52dAe pic.twitter.com/tpiOqIIQjb

— ThoraxBMJ (@ThoraxBMJ) May 23, 2022

 

---

Estudo randomizado | Ozoralizumabe vs. placebo em pacientes com artrite reumatoide ativa a despeito da terapia com metotrexato.

7 Jul, 2022 | 11:49h

Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial) – Arthritis & Rheumatology

Comentário:

---

Estudo randomizado | Acesso radial distal vs. radial convencional para angiografia e intervenção coronarianas.

6 Jul, 2022 | 11:04h

Distal Versus Conventional Radial Access for Coronary Angiography and Intervention: The DISCO RADIAL Trial – JACC Cardiovascular Interventions

Editorial: Less Is More, But Not Always: Distal Transradial Access for Radial Artery Occlusion Prevention

Comentários:

DISCO RADIAL: Distal Radial and Transradial Access Similar When Performed With Rigorous Hemostasis – American College of Cardiology

Distal radial access not better than conventional approach in preventing radial arterial occlusion, DISCO RADIAL Trial – Medical Dialogues

Distal Radial Access Doesn’t Lower Risk of Occlusion: DISCO RADIAL – TCTMD

Fancy Coronary Access Technique Disappoints in Preventing Radial Artery Occlusions — Distal radial approach did result in easier hemostasis, however – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

New #JACCINT issue is out!

RCT shows no difference in radial artery occlusion between distal radial access and transradial access in patients undergoing diagnostic coronary angiography or #PCI using a 6-F Glidesheath Slender. https://t.co/kk5TKgf9rD#RadialFirst #RAO #RCT pic.twitter.com/484yOB9djM

— JACC Journals (@JACCJournals) June 20, 2022

---

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter (fio – clique para saber mais)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials🧵

— The Lancet Haematology (@TheLancetHaem) June 30, 2022

 

---